AlphAIAlphAI — Financial news for AI agents
investing.comOCT 81 min read$ARQT

Jefferies reiterates Arcutis stock Buy rating on Zoryve growth

Jefferies reiterated a Buy rating and $39.00 price target for Arcutis Biotherapeutics (ARQT) due to Zoryve's prescription growth, estimating Q3 2026 sales of $143M. The stock trades at $24.17, below analyst targets. Zoryve's Q3 growth moderated to 8-9% from 13-14% in Q2, with strong margins. Jefferies expects Q4 sales to improve seasonally and forecasts 2026 sales of $525-540M. ARQT reported Q2 2026 revenue of $129.9M, up 59% YoY, and turned profitable.

Original reporting
investing.com
Published Oct 8, 2026, 9:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ARQT
Bullish
medium confidence
Mentioned
$ARQT
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ARQTBullishLow
01

Why it matters

The reiteration of a Buy rating and a $39 target reinforces a positive narrative but does not introduce a material new catalyst.

02

Market read

Minor positive bias for ARQT; limited broader market impact.

03

What to watch

Potential competitive pressure from other PDE4 inhibitors and reimbursement uncertainties could temper upside.

Relevance 4/10Novelty 3/10Timing: today

Background

Arcutis recently posted Q2 revenue beat and moved toward profitability; analyst coverage is expanding.

Company-level read

Ticker impact

$ARQTBullishMedium confidence
Context

Jefferies reiterated a Buy rating and set a $39 price target for Arcutis Biotherapeutics, citing 8‑9% prescription growth for Zoryve in Q3 2026 and strong gross margins.

Expected impact

likely upward pressure as the market prices in the higher target and growth outlook

Evidence & confidence

The rating and target are new analyst actions; no immediate catalyst beyond the note, so impact is limited.

Market effects

Sector

Highlights continued growth in dermatology biotech, may benefit peers with similar pipelines.

Regional

U.S. biotech sector sees modest positive sentiment from the upgrade.

Global

Limited to investors tracking small‑cap biotech stocks.

Counterpoint

What could challenge this read

The upgrade may be premature if prescription growth slows further in the summer season.

Key entities

  • company
    Arcutis Biotherapeutics Inc.

    NASDAQ-listed biotech developing the Zoryve dermatology platform.

  • analyst_firm
    Jefferies

    Equity research firm providing the rating and price target.

Read at source← All news

Related articles

OCT 20
$ARQTHigh

Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb

Arcutis Biotherapeutics (ARQT) shares rose 10.65% to $31.89 after upgrades from Guggenheim and Cantor Fitzgerald, with price targets raised to $44 and $48 respectively. The company reported Q2 net income of $15M, up from a loss last year, driven by its eczema and psoriasis treatment Zoryve. ARQT raised its 2026 sales guidance to $525M-$540M. Institutional investors increased their holdings in Q2.

insidermonkey.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis Shares New Dermatology Data On ZORYVE And Steroid Use; Stock Up

Arcutis Biotherapeutics (ARQT) shared new data on ZORYVE (roflumilast) and steroid use at dermatology conferences. Phase 2 data showed 34.4% of infants with atopic dermatitis achieved clear or almost clear skin after 4 weeks. Phase 3 data showed 66.4% of patients with scalp psoriasis achieved clear or almost clear skin at Week 8. The company also presented research on seborrheic dermatitis and corticosteroid hesitancy. ARQT stock was up 1.32% on Thursday and is up 1.84% in premarket trading.

rttnews.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis presents data on ZORYVE cream for infant eczema

Arcutis Biotherapeutics presented clinical trial data for ZORYVE cream in infants with eczema, showing 34.4% achieved clear or almost clear skin. The treatment had no serious adverse events. The company also shared data on ZORYVE foam for psoriasis, with 66.4% of patients achieving clear or almost clear scalp skin. Arcutis is seeking FDA approval for ZORYVE cream in infants, with a decision expected in 2027.

investing.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Arcutis Biotherapeutics (ARQT) presented data on ZORYVE (roflumilast) at EADV and Fall Clinical Dermatology Conference. The company shared results from the INTEGUMENT-INFANT trial for infants with atopic dermatitis, ARRECTOR and DERMIS-1/2 trials for psoriasis, and collaborative research on seborrheic dermatitis. Additionally, Arcutis presented real-world data on topical corticosteroid use in chronic inflammatory skin conditions.

globenewswire.com2 min